NCT01686048

Brief Summary

Ambrosia is known for its allergenicity in the USA causing hay fever and asthma. Israel has always been considered "clean" of Ambrosia but over the past years growth of Ambrosia plants has been detected in several locations in Israel. In the proposed study, patients referred for routine allergic evaluation will also be skin tested with Ambrosia allergens, in addition to their regular prick skin tests with all other airborne allergens.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Apr 2015

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

September 12, 2012

Completed
5 days until next milestone

First Posted

Study publicly available on registry

September 17, 2012

Completed
2.5 years until next milestone

Study Start

First participant enrolled

April 1, 2015

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2015

Completed
Last Updated

October 7, 2015

Status Verified

October 1, 2015

Enrollment Period

Same day

First QC Date

September 12, 2012

Last Update Submit

October 6, 2015

Conditions

Allergic RhinitisAsthmaAllergic ConjunctivitisAtopic Dermatitis

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients refered for allergic evaluation

You may qualify if:

  • Patients with allergic rhinitis, asthma, allergic conjunctivitis or atopic dermatitis who undergo prick skin tests with airborne allergens

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Arnon Goldberg, M.D., Allergy and Clinical Immunology Unit, Meir Medical Center

Kfar Saba, 44281, Israel

Location

MeSH Terms

Conditions

Rhinitis, AllergicAsthmaConjunctivitis, AllergicDermatitis, Atopic

Condition Hierarchy (Ancestors)

RhinitisNose DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityOtorhinolaryngologic DiseasesHypersensitivity, ImmediateHypersensitivityImmune System DiseasesBronchial DiseasesLung Diseases, ObstructiveLung DiseasesConjunctivitisConjunctival DiseasesEye DiseasesSkin Diseases, GeneticGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesDermatitisSkin DiseasesSkin and Connective Tissue DiseasesSkin Diseases, Eczematous

Study Design

Study Type
observational
Observational Model
CASE ONLY
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head, Allergy and Clinical Immunology Unit

Study Record Dates

First Submitted

September 12, 2012

First Posted

September 17, 2012

Study Start

April 1, 2015

Primary Completion

April 1, 2015

Study Completion

April 1, 2015

Last Updated

October 7, 2015

Record last verified: 2015-10

Locations

IL(1)